INNOVIVA INC. DL-,01INNOVIVA INC. DL-,01INNOVIVA INC. DL-,01

INNOVIVA INC. DL-,01

No trades
See on Supercharts
Market capitalization
‪872.71 M‬EUR
‪−62.56 M‬EUR
‪4.10 M‬EUR
‪62.42 M‬
Beta (1Y)
0.49

About INNOVIVA INC. DL-,01

CEO
Pavel Raifeld
Headquarters
Burlingame
Website
Founded
1996
ISIN
US45781M1018
FIGI
BBG000FQTHK4
Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange INNOVIVA INC. DL-,01 stocks are traded under the ticker HVE.
INNOVIVA INC. DL-,01 is going to release the next earnings report on May 1, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for INNOVIVA INC. DL-,01 has a max estimate of 13.7 EUR and a min estimate of 13.7 EUR.
HVE earnings for the last quarter are 0.93 EUR per share, whereas the estimation was 0.26 EUR resulting in a 262.96% surprise. The estimated earnings for the next quarter are 0.21 EUR per share. See more details about INNOVIVA INC. DL-,01 earnings.
INNOVIVA INC. DL-,01 revenue for the last quarter amounts to ‪63.63 M‬ EUR despite the estimated figure of ‪71.57 M‬ EUR. In the next quarter revenue is expected to reach ‪68.42 M‬ EUR.
Yes, you can track INNOVIVA INC. DL-,01 financials in yearly and quarterly reports right on TradingView.
HVE net income for the last quarter is ‪55.75 M‬ EUR, while the quarter before that showed ‪77.61 M‬ EUR of net income which accounts for −28.17% change. Track more INNOVIVA INC. DL-,01 financial stats to get the full picture.
No, HVE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, HVE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade INNOVIVA INC. DL-,01 stock right from TradingView charts — choose your broker and connect to your account.
HVE reached its all-time high on Jul 12, 2013 with the price of 25.8 EUR, and its all-time low was 3.4 EUR and was reached on Nov 24, 2008.
See other stocks reaching their highest and lowest prices.
We've gathered analysts' opinions on INNOVIVA INC. DL-,01 future price: according to them, HVE price has a max estimate of 13.70 EUR and a min estimate of 13.70 EUR. Read a more detailed INNOVIVA INC. DL-,01 forecast: see what analysts think of INNOVIVA INC. DL-,01 and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. INNOVIVA INC. DL-,01 EBITDA is ‪135.53 M‬ EUR, and current EBITDA margin is −881.39%. See more stats in INNOVIVA INC. DL-,01 financial statements.